Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis
Status:
Completed
Trial end date:
2018-06-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the tolerability, safety, and benefits of an
investigational drug,Fluocinolone Acetonide Intravitreal Insert (FA-i), in people who have
posterior uveitis. The study drug, Fluocinolone Acetonide, is currently used in a surgical
implant, Retisert, which is approved by the U.S. Food and Drug Administration (FDA) to treat
non-infectious posterior uveitis . The study drug is able to be inserted in an ophthalmology
(eye) clinic; whereas Retisert must be surgically implanted in the Operating Room. Initially,
this was a 2-dose randomized pilot study. However, the study was modified to include only the
0.2 ug/day implant.